Background: Losartan and glimepiride are commonly used drugs to treat chronic diseases of hypertension and diabetes; they are both substrates of CYP2C9. The aim of the present study was to investigate the possible interaction of losartan and glimepiride both in vitro (rat liver microsomes) and in vivo (healthy Sprague-Dawley rats). Methods: In rat liver microsomes, 1-10 μmol/l losartan and glimepiride were coincubated, and the inhibitory effect was analyzed. In the subsequent pharmacokinetic study, 15 healthy Sprague-Dawley rats received administrations of 5 mg/kg losartan or 1 mg/kg glimepiride or a coadministration. Results: In the rat liver microsome system, glimepiride showed a slight inhibition of losartan at concentrations of 1-10 μmol/l, whereas losartan exhibited no inhibitory effect on glimepiride. In vivo, glimepiride did not modify the plasma concentration of losartan and its metabolite E-3174. The alteration of an increased AUC and Cmax was observed in the pharmacokinetic parameters of glimepiride and hydroxy glimepiride. Conclusions: Glimepiride did not affect losartan pharmacokinetics in rats, while losartan potently altered glimepiride metabolism; this result was inconsistent with the in vitro outcome. The mechanism requires further investigation. In clinical settings, attention should be paid to the interaction of these two drugs in the human body as well as the possible adverse reactions of glimepiride.

Jarrar YB, Lee SJ: Molecular functionality of CYP2C9 polymorphisms and their influence on drug therapy. Drug Metabol Drug Interact 2014;29:211-220.
Samer CF, Lorenzini KI, Rollason V, Daali Y, Desmeules JA: Applications of CYP450 testing in the clinical setting. Mol Diagn Ther 2013;17:165-184.
Kuroda Y, Saito M, Sakai H, Yamaoka T: Rapid characterization of drug-drug interaction in plasma protein binding using a surface plasmon resonance biosensor. Drug Metab Pharmacokinet 2008;23:120-127.
Emoto C, Fukuda T, Cox S, Christians U, Vinks AA: Development of a physiologically-based pharmacokinetic model for sirolimus: predicting bioavailability based on intestinal CYP3A content. CPT Pharmacometrics Syst Pharmacol 2013;2:e59.
Zakeri-Milani P, Valizadeh H: Intestinal transporters: enhanced absorption through P-glycoprotein-related drug interactions. Expert Opin Drug Metab Toxicol 2014;10:859-871.
Stearns RA, Chakravarty PK, Chen R, Chiu SH: Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members. Drug Metab Dispos 1995;23:207-215.
Cabaleiro T, Roman M, Ochoa D, Talegon M, Prieto-Perez R, Wojnicz A, Lopez-Rodriguez R, Novalbos J, Abad-Santos F: Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. Drug Metab Dispos 2013;41:224-229.
Sandberg M, Johansson I, Christensen M, Rane A, Eliasson E: The impact of CYP2C9 genetics and oral contraceptives on cytochrome P450 2C9 phenotype. Drug Metab Dispos 2004;32:484-489.
Kamiyama E, Yoshigae Y, Kasuya A, Takei M, Kurihara A, Ikeda T: Inhibitory effects of angiotensin receptor blockers on CYP2C9 activity in human liver microsomes. Drug Metab Pharmacokinet 2007;22:267-275.
Choi JS, Choi JS, Choi DH: Effects of licochalcon A on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rats. Pharmazie 2013;68:882-888.
Dai DP, Wang SH, Geng PW, Hu GX, Cai JP: In vitro assessment of 36 CYP2C9 allelic isoforms found in the Chinese population on the metabolism of glimepiride. Basic Clin Pharmacol Toxicol 2014;114:305-310.
Iwakawa S, Miyashita K, Hashimoto Y, Kuroda T: Effect of glimepiride and glibenclamide on S-warfarin 7-hydroxylation by human liver microsomes, recombinant human CYP2C9.1 and CYP2C9.3. Biol Pharm Bull 2006;29:1983-1985.
Lee CR, Pieper JA, Hinderliter AL, Frye RF, Blaisdell JA, Goldstein JA: Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans. J Clin Pharmacol 2003;43:84-91.
Yasar Ü, Tybring G, Hidestrand M, Oscarson M, Ingelman-Sundberg M, Dahl M-L, Eliasson E: Role of CYP2C9 polymorphism in losartan oxidation. Drug Metab Dispos 2001;29:1051-1056.
Meadowcroft AM, Williamson KM, Patterson JH, Hinderliter AL, Pieper JA: The effects of fluvastatin, a CYP2C9 inhibitor, on losartan pharmacokinetics in healthy volunteers. J Clin Pharmacol 1999;39:418-424.
Guenette L, Breton MC, Hamdi H, Gregoire JP, Moisan J: Important treatment gaps in vascular protection for the elderly after type 2 diabetes therapy initiation. Can J Cardiol 2013;29:1593-1598.
Chen SZ, Pan PP, Shen LB, Xu SS, Dai DP, Geng PW, Cai J, Cai JP, Hu GX: Drug-drug interaction of losartan and glimepiride metabolism by recombinant microsome CYP2C9*1, 2C9*3, 2C9*13, and 2C9*16 in vitro. Int J Clin Pharmacol Ther 2014;52:732-738.
Wang YH, Pan PP, Dai DP, Wang SH, Geng PW, Cai JP, Hu GX: Effect of 36 CYP2C9 variants found in the Chinese population on losartan metabolism in vitro. Xenobiotica 2014;44:270-275.
Yang SH, Choi JS, Choi DH: Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors. Pharmacology 2011;88:1-9.
Murakami T, Fukuda T, Yumoto R, Nagai J, Kuramoto T, Takano M: Interaction of endogenous compounds in human and rat urine with P-glycoprotein. Drug Metab Pharmacokinet 2002;17:245-252.
Shumaker RC, Aluri J, Fan J, Martinez G, Thompson GA, Ren M: Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults. Clin Drug Investig 2014;34:651-659.
Kobori T, Harada S, Nakamoto K, Tokuyama S: Effect of repeated oral treatment with etoposide on the expression of intestinal P-glycoprotein and oral morphine analgesia (in Japanese). Yakugaku Zasshi 2014;134:689-699.
Kamiyama E, Nakai D, Mikkaichi T, Okudaira N, Okazaki O: Interaction of angiotensin II type 1 receptor blockers with P-gp substrates in Caco-2 cells and hMDR1-expressing membranes. Life Sci 2010;86:52-58.
Weiss J, Sauer A, Divac N, Herzog M, Schwedhelm E, Boger RH, Haefeli WE, Benndorf RA: Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters. Biopharm Drug Dispos 2010;31:150-161.
Langtry HD, Balfour JA: Glimepiride. A review of its use in the management of type 2 diabetes mellitus. Drugs 1998;55:563-584.
Seedher N, Kanojia M: Fluorescence spectroscopic study for competitive binding of antidiabetic drugs and endogenous substances on serum albumin. Drug Metabol Drug Interact 2013;28:107-114.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.